Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.

Published Date: 30 Aug 2023

According to recent studies presented in a Hot Line session, twelve months of edoxaban is superior to three months for reducing thrombotic events in patients with cancer and distal deep vein thrombosis (DVT).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Five new papers highlight cancer inequities, challenges and opportunities in South Asia

2.

Alkem introduces cetuximab under the trade name Cetuxa in India.

3.

Atezolizumab + Cabozantinib Postpones mCRPC Progression.

4.

Researchers have determined that malignancy hibernation will be the next front in the fight against breast cancer.

5.

More evidence links physical activity with improved cancer survival


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot